BR112023009172A2 - Métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a - Google Patents

Métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a

Info

Publication number
BR112023009172A2
BR112023009172A2 BR112023009172A BR112023009172A BR112023009172A2 BR 112023009172 A2 BR112023009172 A2 BR 112023009172A2 BR 112023009172 A BR112023009172 A BR 112023009172A BR 112023009172 A BR112023009172 A BR 112023009172A BR 112023009172 A2 BR112023009172 A2 BR 112023009172A2
Authority
BR
Brazil
Prior art keywords
tl1a
kits
systems
methods
treatment
Prior art date
Application number
BR112023009172A
Other languages
English (en)
Inventor
T Dickerson Cindy
Dalin Li
P Mcgovern Dermot
Janine Bilsborough
D Watkins Jeffry
Laurens Kruidenier
Mahyar Sabripour
Matthew Reissman
Patricia Mcneeley
Rafael Rojas
Original Assignee
Cedars Sinai Medical Center
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, Prometheus Biosciences Inc filed Critical Cedars Sinai Medical Center
Publication of BR112023009172A2 publication Critical patent/BR112023009172A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a. são fornecidos métodos, sistemas e kits para selecionar um sujeito para tratamento com um inibidor da atividade ou expressão da citocina 1a semelhante ao fator de necrose tumoral (tl1a) com base na presença de um ou mais genótipos associados a uma resposta terapêutica positiva ao inibidor de tl1a. também são fornecidos métodos, sistemas e kits para detectar um ou mais genótipos descritos neste documento.
BR112023009172A 2020-11-13 2021-11-11 Métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a BR112023009172A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063113657P 2020-11-13 2020-11-13
US202163136153P 2021-01-11 2021-01-11
US202163147165P 2021-02-08 2021-02-08
US202163181074P 2021-04-28 2021-04-28
US202163226032P 2021-07-27 2021-07-27
PCT/US2021/058979 WO2022103961A1 (en) 2020-11-13 2021-11-11 Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a

Publications (1)

Publication Number Publication Date
BR112023009172A2 true BR112023009172A2 (pt) 2023-10-03

Family

ID=81602611

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023009172A BR112023009172A2 (pt) 2020-11-13 2021-11-11 Métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a

Country Status (12)

Country Link
US (1) US20230272098A1 (pt)
EP (1) EP4244251A1 (pt)
JP (1) JP2023551602A (pt)
KR (1) KR20230140553A (pt)
AU (1) AU2021377688A1 (pt)
BR (1) BR112023009172A2 (pt)
CA (1) CA3197828A1 (pt)
CO (1) CO2023007607A2 (pt)
IL (1) IL302791A (pt)
MX (1) MX2023005688A (pt)
TW (1) TW202233685A (pt)
WO (1) WO2022103961A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202043234A (zh) 2019-01-24 2020-12-01 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
WO2022232253A1 (en) * 2021-04-28 2022-11-03 Cedars-Sinai Medical Center Patient selection methods and kits for therapies targeting tl1a

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0004928D0 (sv) * 2000-12-29 2000-12-29 Apbiotech Ab A method for the manufacturing of porous material
BR0116763A (pt) * 2000-12-29 2004-03-09 Bio Technology General Corp Anticorpos humanos especìficos para terapia seletiva do c ncer
US10626180B2 (en) * 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
JP7332627B2 (ja) * 2018-04-25 2023-08-23 プロメテウス バイオサイエンシーズ，インク． 最適化された抗ｔｌ１ａ抗体

Also Published As

Publication number Publication date
TW202233685A (zh) 2022-09-01
AU2021377688A1 (en) 2023-06-29
CA3197828A1 (en) 2022-05-19
WO2022103961A1 (en) 2022-05-19
IL302791A (en) 2023-07-01
US20230272098A1 (en) 2023-08-31
JP2023551602A (ja) 2023-12-08
KR20230140553A (ko) 2023-10-06
EP4244251A1 (en) 2023-09-20
CO2023007607A2 (es) 2023-06-30
MX2023005688A (es) 2023-07-18

Similar Documents

Publication Publication Date Title
BR112023009172A2 (pt) Métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
EP4085919A3 (en) Compositions and methods to treat cancer
Tate et al. An update on the NLRP3 inflammasome and influenza: the road to redemption or perdition?
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
BR112017026467A2 (pt) uso de exossomos para o tratamento de doença
CY1119451T1 (el) Αντισωμα που αναγνωριζει τον ανθρωπινο ανασταλτικο παραγοντα λευχαιμιας (lif) και η χρηση των anti-lif αντισωματων στη θεραπεια παθησεων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο
BR112021022789A2 (pt) Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
EA202091673A1 (ru) Способ амплификации нуклеиновых кислот
UY30097A1 (es) Usos terapeuticos de inhibidores de rtp801
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
MX2017015922A (es) Biomarcadores asociados con inhibidores de lsd1 y usos de los mismos.
CO2022000481A2 (es) Inhibidores de enzimas
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
BR112023001957A2 (pt) Composições e métodos para inibir expressão de lpa
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
EA202193038A1 (ru) Антитела против sema3a и их применения для лечения заболеваний глаз
EA202192746A1 (ru) Гетероциклические соединения и их применение
MX2022005547A (es) Derivados terapeuticos de interleucina-22.
BR112022007932A2 (pt) Métodos para tratamento de leucemia e uso de uma assinatura de células-tronco leucêmicas para predizer sensibilidade clínica a terapias
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
CL2021001363A1 (es) Métodos de tratamiento de enfermedades con inhibidores de magl.
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.